{"url_path":"/sec/pvct/8-k/2026-06-18/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-18","source_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-029280-index.html","accession_number":"0001493152-26-029280","cik":"0000315545","ticker":"PVCT","issuer_name":"PROVECTUS BIOPHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/315545/0001493152-26-029280-index.html","primary_entity_key":"0000315545","primary_entity_name":"PROVECTUS BIOPHARMACEUTICALS, INC."},"word_count":125,"has_tables":true,"body_markdown":"** **\n\n**Item\n7.01. Regulation FD Disclosure.**\n\n \n\nDuring\nits annual meeting of stockholders to be held on June 18, 2026, Provectus Biopharmaceuticals, Inc. (the “Company”) will provide\nan update about the Company’s clinical development, regulatory affairs, drug discovery, manufacturing, intellectual property, business\ndevelopment, and corporate development activities.\n\n \n\nA\ncopy of the Company’s 2026 Annual Meeting of Stockholders presentation slides is attached to this Current Report on Form 8-K as\nExhibit 99.1 and is incorporated herein by reference.\n\n \n\nPursuant\nto the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit\n99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the\nSecurities Exchange Act of 1934, as amended."}